<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140126</url>
  </required_header>
  <id_info>
    <org_study_id>UBI Protocol A101</org_study_id>
    <secondary_id>Protocol A101-HIV</secondary_id>
    <nct_id>NCT01140126</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults</brief_title>
  <official_title>A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Biomedical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase I study is to determine whether the antibody (UB-421), targeting
      the HIV-1 receptor on the CD4 molecule (domain 1) of T-lymphocytes and monocytes, is safe and
      well tolerated when administered to asymptomatic HIV-1 infected adults by intravenous
      infusion and to assess pharmacokinetic parameters of the antibody in blood and on cells. The
      neutralizing activity of UB-421 blocks HIV-1 from binding to its receptor on CD4-positive
      cells; thus, UB-421 functions as an immunotherapeutic intervention to prevent HIV-1
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of a single intravenous infusion at escalating doses of UB-421.</measure>
    <time_frame>Screen, treatment &amp; follow-up: 62 to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine pharmacokinetic parameters of a single intravenous infusion at escalating doses of UB-421.</measure>
    <time_frame>Screen, treatment &amp; follow-up: 62 to 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV-1 Infection in Adults (Asymptomatic)</condition>
  <arm_group>
    <arm_group_label>Antibody (UB-421)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibody UB-421</intervention_name>
    <description>Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.</description>
    <arm_group_label>Antibody (UB-421)</arm_group_label>
    <other_name>N.A.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic, treatment-naive, HIV-1 seropositive

          -  CD4+ T cell count &gt;350 cells/cubic millimeter

          -  HIV-1 viral load &gt;5,000 copies/mL

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  Active infection requiring immediate therapy (except HIV-1)

          -  Prior participation in any HIV vaccine trial

          -  Previous exposure to a monoclonal antibody

          -  Use of immunomodulating drugs or systemic chemotherapy

          -  Other exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wing Wai Wong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital (TVGH), Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hung Chin Tsai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital (KVGH), Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (TVGH)</name>
      <address>
        <city>Taipei City</city>
        <state>Beitou District</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital (KVGH)</name>
      <address>
        <city>Kaohsiung City</city>
        <state>Zuoying District</state>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://patft.uspto.gov/netahtml/PTO/srchnum.htm</url>
    <description>S Lynn and CY Wang. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection. U.S. Patent No. 7,501,494</description>
  </link>
  <reference>
    <citation>Wang CY, Sawyer LS, Murthy KK, Fang X, Walfield AM, Ye J, Wang JJ, Chen PD, Li ML, Salas MT, Shen M, Gauduin MC, Boyle RW, Koup RA, Montefiori DC, Mascola JR, Koff WC, Hanson CV. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10367-72.</citation>
    <PMID>10468614</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2010</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wing Wai Wong, M.D.</name_title>
    <organization>Taipei Veterans General Hospital (TVGH), Taiwan</organization>
  </responsible_party>
  <keyword>HIV-1, CD4, antibody, immunotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

